RNA Fusion Gene Panel (For Illumina® Platforms)

Cat Number: RFGP-NGS

The RNA Fusion Gene Panel is a multiplexed next-generation sequencing assay designed to detect key oncogenic gene fusions across 23 clinically relevant cancer genes for comprehensive transcript-level profiling.

Covers and detects 305 fusion genes across 23 genes
Includes reagents for reverse transcription, target enrichment; library preparation, clean up, sample and library QC
Compatible with Illumina® NextSeq 500, MiniSeq, and MiSeq sequencers
Complimentary data-analysis software for local installation available
40 tests per kit
For research use (RUO) in the U.S
For in vitro diagnostic use (IVD) in the European Union

Category: Pan Cancers Tags: ABL1, AKT3, ALK, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

Request More Information

The RNA Fusion Gene Panel is a next-generation sequencing (NGS) assay designed to detect oncogenic gene fusion events in a broad spectrum of solid tumors and hematologic malignancies.

These fusion events are frequently observed across multiple tumor types and play critical roles in cancer development by driving constitutive activation of signaling pathways such as MAPK and PI3K.

The RNA Fusion Gene Panel utilizes a highly multiplexed, PCR-based target enrichment strategy to amplify 305 known fusion transcripts with an average amplicon size of 145 base pairs. The assay includes reagents for reverse transcription, indexed PCR, and adapter ligation, generating libraries compatible with Illumina® sequencing platforms.

The kit provides all necessary components for fusion gene detection and library preparation, and is validated for use with RNA derived from a variety of sources including FFPE tissues, blood, fresh or frozen samples, and cultured cells. EntroGen’s Variant Analysis (EVA) software supports data interpretation with a user-friendly interface that reports fusion gene identities along with genomic breakpoint positions.

For laboratories focused on transcriptome-level tumor profiling, the RNA Fusion Gene Panel offers a robust and efficient tool for the sensitive detection of fusion events relevant to precision oncology research.

The panel targets fusion transcripts involving 23 cancer-associated genes:

Gene	Number of Detected Fusions
ABL	1
ALK	61
AKT3	1
AXL	1
BRAF	15
EGFR	2
ERBB2	1
ERG	16
ETV1	4
ETV4	1
ETV5	3
FGFR1	4
FGFR2	10
FGFR3	25
MET	10
NTRK1	34
NTRK2	18
NTRK3	16
PDGFRA	1
PPARG	4
RAF1	2
RET	41
ROS1	34

For More Information

The RNA Fusion Gene Panel provides a streamlined and efficient next-generation sequencing (NGS) workflow for the detection of oncogenic gene fusion events in cancer-associated transcripts. The assay is compatible with RNA extracted from blood, fresh frozen tissues, and high-quality FFPE samples, and is optimized for use on Illumina® sequencing platforms.

This kit includes reagents required for reverse transcription, target enrichment, library preparation, and indexing to ensure accurate and sensitive detection of fusion transcripts. The workflow involves RNA quantification, cDNA synthesis through reverse transcription, highly multiplexed PCR-based enrichment of fusion targets, and adaptor ligation, followed by purification and generation of NGS-ready libraries.

Reagents and columns for RNA isolation are not included. To ensure optimal assay performance, RNA input should be quantified using a fluorometric or qPCR-based method prior to reverse transcription and library preparation.

The Library Quantification Kit for Illumina® (EntroGen, catalog no. LIBQ-NGS) is recommended, but not included with this kit.